These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 2153477)

  • 1. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.
    Hondeghem LM; Snyders DJ
    Circulation; 1990 Feb; 81(2):686-90. PubMed ID: 2153477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardiac vulnerable period and reentrant arrhythmias: targets of anti- and proarrhythmic processes.
    Starmer CF
    Pacing Clin Electrophysiol; 1997 Feb; 20(2 Pt 2):445-54. PubMed ID: 9058848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New class III antiarrhythmic drugs.
    Katritsis D; Camm AJ
    Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
    Hondeghem LM; Carlsson L; Duker G
    Circulation; 2001 Apr; 103(15):2004-13. PubMed ID: 11306531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To prolong refractoriness or to delay conduction (or both)?
    Janse MJ
    Eur Heart J; 1992 Nov; 13 Suppl F():14-8. PubMed ID: 1335868
    [No Abstract]   [Full Text] [Related]  

  • 9. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates.
    Roden DM
    Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial (ESVEM) Investigators.
    Freedman RA; Steinberg JS
    J Am Coll Cardiol; 1991 Apr; 17(5):1017-25. PubMed ID: 1848871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of spiral wave reentry by K(+) channel blockade.
    Honjo H; Yamazaki M; Kamiya K; Kodama I
    Circ J; 2007; 71 Suppl A():A26-31. PubMed ID: 17587736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism.
    Franz MR; Gray RA; Karasik P; Moore HJ; Singh SN
    Europace; 2014 Nov; 16 Suppl 4():iv39-iv45. PubMed ID: 25362169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-arrhythmic and cardiodepressive effects of anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1988; 77 Suppl 5():113-9. PubMed ID: 2464875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postrepolarization refractoriness in acute ischemia and after antiarrhythmic drug administration: action potential duration is not always an index of the refractory period.
    Coronel R; Janse MJ; Opthof T; Wilde AA; Taggart P
    Heart Rhythm; 2012 Jun; 9(6):977-82. PubMed ID: 22293142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of Proarrhythmic Effects of Potassium Channel Blockers.
    Skibsbye L; Ravens U
    Card Electrophysiol Clin; 2016 Jun; 8(2):395-410. PubMed ID: 27261830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New aspects of the molecular effect of anti-arrhythmia agents].
    Honerjäger P
    Herz; 1990 Apr; 15(2):70-8. PubMed ID: 2160907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling cardiac arrhythmias by lengthening repolarization: historical overview.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):18F-24F. PubMed ID: 8237826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.